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OBJECTIVES We sought to develop national benchmarks for valve replacement surgery by developing
statistical risk models of operative mortality.
BACKGROUND National risk models for coronary artery bypass graft surgery (CABG) have gained
widespread acceptance, but there are no similar models for valve replacement surgery.
METHODS The Society of Thoracic Surgeons National Cardiac Surgery Database was used to identify
risk factors associated with valve surgery from 1994 through 1997. The population was drawn
from 49,073 patients undergoing isolated aortic valve replacement (AVR) or mitral valve
replacement (MVR) and from 43,463 patients undergoing CABG combined with AVR or
MVR. Two multivariable risk models were developed: one for isolated AVR or MVR and one
for CABG plus AVR or CABG plus MVR.
RESULTS Operative mortality rates for AVR, MVR, combined CABG/AVR and combined CABG/
MVR were 4.00%, 6.04%, 6.80% and 13.29%, respectively. The strongest independent risk
factors were emergency/salvage procedures, recent infarction, reoperations and renal failure.
The c-indexes were 0.77 and 0.74 for the isolated valve replacement and combined
CABG/valve replacement models, respectively. These models retained their predictive
accuracy when applied to a prospective patient population undergoing operation from 1998
to 1999. The Hosmer-Lemeshow goodness-of-fit statistic was 10.6 (p 5 0.225) for the
isolated valve replacement model and 12.2 (p 5 0.141) for the CABG/valve replacement
model.
CONCLUSIONS Statistical models have been developed to accurately predict operative mortality after valve
replacement surgery. These models can be used to enhance quality by providing a national
benchmark for valve replacement surgery. (J Am Coll Cardiol 2001;37:885–92) © 2001 by
the American College of Cardiology
Risk stratification has become an essential element in the
practice of cardiac surgery (1). In the field of coronary artery
bypass graft surgery (CABG), numerous studies have iden-
tified the most important patient risk factors and have
confirmed the advantage of risk-adjusted results compared
with raw mortality statistics (2–6). Unfortunately, outcomes
research in valve replacement surgery has been relatively
limited.
Using data from the Society of Thoracic Surgeons Na-
tional Cardiac Surgery Database (STS Database), we char-
acterized operative outcomes after isolated valve replace-
ment and CABG plus valve surgery. We identified major
preoperative predictors of mortality and developed risk
models that would accurately estimate operative mortality
(OM). We then assessed the performance of these models
in a prospective patient population.
METHODS
The STS Database. The STS Database was initiated in
1986 and now contains detailed clinical information on
more than one million registered patients undergoing car-
diac surgery. In total, over 487 academic, private, military
and Veterans Affairs hospitals from 47 U.S. states and five
Canadian provinces participate.
Participants in the STS Database receive individualized,
semi-annual, risk-adjusted surgery outcomes, along with
direct comparisons with the aggregate database population.
This feedback is used for internal quality improvement
efforts and is not publicly released. The mortality risk
models are an integral part of the participants’ software,
which allows the users to generate risk-adjusted outcomes
data locally, compared with the national experience.
Patient population. The models were developed using
data on all patients undergoing aortic valve replacement
(AVR) or mitral valve replacement (MVR) either alone or
in combination with CABG from January 1, 1994 through
December 31, 1997. This included those patients receiving
either mechanical or bioprosthetic valve replacement, but
excluded those receiving valve repair surgery. In addition,
patient records were excluded from the study if they were
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missing age or gender (,0.1% of records), if they were
receiving tricuspid or pulmonary valve surgery or if they
were having multivalve replacement surgery. In addition, all
patients having a diagnosis of congenital heart disease were
excluded. Finally, those undergoing cardiac surgery com-
bined with other cardiac procedures were excluded. The
resultant database contains clinical information on 92,536
patients. A total of 49,073 patients received isolated AVR or
MVR, and 43,463 patients received combined CABG/valve
surgery.
The external validation sample consisted of 51,492 pa-
tients in the STS Database who received valve replacement
from January 1, 1998 to December 31, 1999. In this group,
25,640 patients received isolated valve replacement, whereas
the remaining 25,852 patients underwent combined
CABG/valve surgery.
Data definitions. Operative mortality is defined as 1) all
deaths occurring during the hospital period in which the
operation was performed; and 2) those deaths occurring
after hospital discharge, but within 30 days of the proce-
dure, unless the cause of death is clearly unrelated to the
operation. Definitions of risk factors used in this analysis are
provided in the STS web site.
Analysis. Each of the STS “core data set” risk factors were
considered for inclusion into the model. Patient demo-
graphic data were compared (Table 1), and univariate OM
rates for each risk factor were examined. This information,
along with clinical evaluation of the risk factors, was used
to determine the model variables. We constructed two
models—one that included isolated valve procedures (AVR
and MVR) and another that included combined (CABG
plus valve replacement) procedures.
For modeling purposes, the median value was used to
replace missing values for continuous variables, whereas
missing categorical values were replaced with the most
prevalent value. With these standard assumptions, all pa-
tients in the population were included in the modeling
process. For each model, stepwise logistic regression was
performed to determine those factors that were most sig-
nificantly associated with OM. In the stepwise process,
variables were entered and removed according to whether
the Wald p values were ,0.10 for entry and ,0.01 for
Abbreviations and Acronyms
AVR 5 aortic valve replacement
BSA 5 body surface area
CABG 5 coronary artery bypass grafting
MI 5 myocardial infarction
MVR 5 mitral valve replacement
OM 5 operative mortality
STS 5 Society of Thoracic Surgeons
STS Database 5 Society of Thoracic Surgeons National
Cardiac Surgery Database
US 5 United States
Table 1. Risk Factors and Outcome Variable
AVR
Only
MVR
Only
CABG/
AVR
CABG/
MVR
Patient age (yrs)
25th percentile 56.0 52.0 67.0 63.0
Mean value 64.8 61.3 71.6 68.7
Median value 68.0 64.0 73.0 70.0
75th percentile 75.0 72.0 78.0 75.0
Unknown 0.0 0.0 0.0 0.0
Gender (%)
Male 58.6 38.0 67.5 51.1
Female 41.4 62.0 32.5 48.9
Race (%)
Caucasian 86.2 82.3 91.2 89.4
Black 5.2 7.8 2.8 4.2
Hispanic 2.9 3.3 1.6 1.8
Asian 0.8 1.7 0.6 0.9
Native American 0.3 0.5 0.1 0.2
Other 0.9 1.3 0.8 0.8
Unknown 3.5 3.2 2.9 2.7
Body surface area (m2)
25th percentile 1.72 1.62 1.73 1.67
Mean value 1.88 1.79 1.88 1.82
Median value 1.88 1.78 1.89 1.82
75th percentile 2.04 1.95 2.04 1.98
Unknown 0.06 0.06 0.06 0.07
Morbid obesity (%)
Yes 12.9 10.8 10.1 9.5
Unknown 4.1 4.1 4.3 4.5
History of smoking (%)
Yes 44.9 40.8 50.6 51.4
Unknown 5.0 5.6 4.7 4.8
Current smoker (%)
Yes 13.4 13.2 12.5 16.0
Unknown 14.6 15.4 15.3 15.9
Family history of CAD (%)
Yes 26.4 23.5 35.7 35.1
Unknown 9.0 9.9 7.7 7.9
Diabetes (%)
Yes 14.7 11.3 24.7 25.8
Unknown 5.8 6.8 5.1 5.3
Hypercholesterolemia (%)
Yes 25.6 20.1 38.2 34.9
Unknown 8.2 9.7 6.7 7.4
Renal failure (%)
Yes 2.8 3.8 3.5 5.7
Unknown 7.0 7.8 6.5 6.6
Last creatinine level
(mg/100 ml)
25th percentile 1.0 1.0 1.0 1.1
Mean value 2.1 2.2 2.0 2.2
Median value 1.2 1.3 1.4 1.7
75th percentile 2.0 2.3 2.1 2.5
Unknown 0.9 0.9 0.9 0.9
Dialysis (%)
Yes 0.9 1.2 0.8 0.9
Unknown 13.1 12.3 10.9 11.5
Hypertension (%)
Yes 47.9 37.2 61.1 57.0
Unknown 4.5 5.9 3.8 4.2
CVA (%)
Recent (#2 weeks) 0.4 1.1 0.3 0.6
Remote (.2 weeks) 4.8 7.7 6.9 8.6
Unknown 7.9 9.0 7.6 6.3
(continued on next page)
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retention. Logistic regression models were then developed
in this form:
P 5 1/~1 1 exp@ 2 X#!
where P is the probability of postoperative death; and X 5
B0 1 B1X1 1 B2X2 1 . . . 1 BkXk, where k is the number
of risk factors in the model; Bi is the constant associated
with the ith risk factor; and Xi indicates the status of the i
th
risk factor for an individual patient.
Assessment of model performance. Model performance
was assessed both internally and externally. The internal
approach involved direct comparison of predicted versus
observed results within the data on which the model was
derived. The c-index, which reflects the ability of a model to
discriminate patients who died during the operation from
survivors, was calculated to evaluate model discrimination.
For model calibration, patients were ordered by their
predicted OM and then classified into 10 groups of equal
size. Average predicted versus observed OM rates were then
compared for each of the groups across the risk spectrum.
We also tested the model in a population separate from
the derived population. For this independent data set, we
selected registered patients undergoing operation in 1998 or
1999. The screening criteria described earlier were applied
to all patients in this database, yielding 25,640 patients in
the “isolated valve test set” and 25,852 patients in the
“CABG plus valve test set.” Average predicted and observed
OM rates were then compared for each group. The c-index
for the model applied to this population was also calculated.
RESULTS
Patient demographic data. Of the 92,536 patients, 32,968
had AVR; 16,105 had MVR; 32,538 had CABG/AVR; and
10,925 had CABG/MVR. The clinical characteristics of
these four patient groups are shown in Table 1. Compared
with those receiving combined CABG/valve surgery, those
receiving isolated valve procedures (AVR or MVR) were
younger and tended to have fewer cardiac risk factors.
Patients undergoing MVR were younger, had a smaller
Table 1. Continued
AVR
Only
MVR
Only
CABG/
AVR
CABG/
MVR
Infectious endocarditis (%)
Yes 5.3 9.6 1.5 3.5
Unknown 8.2 8.6 8.0 8.5
Immunosuppressive treatment (%)
Yes 2.0 2.3 1.9 2.1
Unknown 9.2 10.1 8.6 9.1
Peripheral vascular disease (%)
Yes 6.6 5.5 14.7 13.7
Unknown 9.1 10.2 8.0 8.5
Cerebrovascular disease (%)
Yes 6.8 7.8 12.2 11.1
Unknown 9.8 11.1 8.7 9.4
Previous cardiac operation (%)
Yes 15.7 30.0 14.1 19.3
Unknown 0.5 0.4 0.3 0.3
Myocardial infarction (%)
,6 h 0.0 0.1 0.2 1.2
6–24 h 0.1 0.2 0.4 1.9
1–7 days 0.6 1.0 4.0 11.1
8–21 days 0.6 0.8 2.8 5.6
.21 days 5.2 5.8 15.9 20.2
Unknown 10.3 8.5 7.2 7.0
Congestive heart failure (%)
Yes 41.6 60.2 40.1 61.9
Unknown 7.0 5.9 6.1 4.6
Cardiogenic shock (%)
Yes 3.8 7.0 5.1 16.5
Unknown 8.1 7.9 6.6 5.7
Resuscitation (%)
Yes 0.6 1.0 0.9 2.4
Unknown 9.8 9.8 8.3 8.0
Arrhythmia (%)
Yes 19.7 49.2 19.9 38.1
Unknown 7.8 6.0 6.5 5.7
CCS classification
0 0.1 0.1 0.0 0.0
I 17.6 19.8 7.8 8.1
II 11.9 7.7 11.6 8.1
III 23.6 22.1 31.7 26.2
IV 9.4 12.0 17.4 25.8
Unknown 37.4 38.2 31.5 31.9
NYHA classification
I 7.6 4.9 5.6 3.6
II 15.6 11.1 12.6 8.2
III 38.2 39.5 39.3 34.5
IV 16.1 22.5 21.3 32.9
Unknown 22.5 22.0 21.3 20.8
Inotropic support (%)
Yes 2.4 4.9 2.5 10.0
Unknown 14.0 14.2 13.6 14.2
Triple-vessel disease (%)
Yes 1.0 0.9 38.3 42.8
Unknown 95.5 96.1 3.6 3.9
LMCA disease .50% (%)
Yes 0.4 0.3 12.8 11.1
Unknown 63.6 64.9 4.5 5.2
Ejection fraction (%)
25th percentile 41.0 45.0 40.0 38.0
Mean value 51.9 54.1 49.8 47.6
Median value 51.0 55.0 50.0 48.0
75th percentile 60.0 60.0 60.0 60.0
Unknown 0.3 0.3 0.2 0.2
(continued)
Table 1. Continued
AVR
Only
MVR
Only
CABG/
AVR
CABG/
MVR
Operative status (%)
Elective 82.2 77.7 74.5 63.4
Urgent 14.4 16.0 21.7 24.3
Emergency 1.7 3.7 2.3 7.9
Salvage 0.5 1.2 0.4 3.0
Unknown 1.3 1.4 1.1 1.4
Intraoperative balloon pump (%)
Preoperative 0.7 3.6 2.2 13.7
Intraoperative 2.0 2.7 5.2 7.9
Postoperative 1.5 2.3 1.8 2.7
Unknown 3.5 2.6 3.5 2.9
AVR 5 aortic valve replacement; CABG 5 coronary artery bypass graft surgery;
CAD 5 coronary artery disease; CCS 5 Canadian Cardiovascular Society; CVA 5
cerebrovascular accident; LMCA 5 left main coronary artery; MVR 5 mitral valve
replacement; NYHA 5 New York Heart Association.
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body surface area, were more likely to have had previous
cardiac surgery and had a higher incidence of congestive
heart failure and cardiogenic shock, compared with those
receiving AVR.
Patient outcomes. Outcomes for the four procedural
groups are presented in Table 2. Operative mortality was
higher in those receiving combined procedures than in those
receiving isolated valve surgery. Likewise, OM was higher
in those receiving MVR than in those receiving AVR.
Higher complication rates and longer postoperative hospital
stays were also noted in those receiving combined CABG/
valve surgery (vs. isolated valve surgery) and in those
receiving mitral (vs. aortic) valve procedures.
Operative mortality risk factors. Certain preoperative
clinical characteristics markedly increased the risk of mor-
tality after valve surgery. Table 3 provides OM rates in
specific subsets of patients receiving valve surgery. As
indicated previously, our strategy was to build two models—
one for isolated valve procedures and one for combined
(CABG plus valve replacement) procedures. Tables 4 and 5
show the independent risk factors that emerged for these
two models, excluding those factors demonstrating signifi-
cant interactions. In patients having isolated valve replace-
ment, the factors most strongly associated with an adverse
outcome were the need for reoperation, emergency opera-
tion and the presence of renal failure (Table 4). These same
factors were also the most prominent in the CABG/valve
replacement group (Table 5). Although the two models
contain similar risk predictors in general, the combined
CABG/valve replacement procedure has a number of risk
factors traditionally associated with coronary artery disease.
In addition, most clinical factors had a similar impact on
risk in both AVR and MVR. For the isolated valve model,
age was the only risk factor that had a significant interaction
with the type of valve replacement, indicating that MVR,
but not AVR, is associated with an adverse odds ratio that
increases with age. The isolated valve model also included
an interaction between emergency/salvage status and age.
Emergency/salvage status had less influence on older pa-
tients. The CABG/valve model included four risk factor
interactions: the risk associated with previous cardiac oper-
ation(s), pulmonary hypertension, salvage status and periph-
eral vascular disease was increased among the MVR group
compared with the AVR group. The CABG/valve model
also contains an interaction between age and previous
cardiac operation(s), indicating that older patients who have
had at least one previous cardiac operation have a greater
risk of dying compared with younger patients.
Table 2. Outcomes
Outcome AVR MVR CABG/AVR CABG/MVR
Operative mortality (%) 4.00 6.04 6.80 13.29
Complications (%)
Permanent stroke 1.58 2.16 3.15 4.46
Prolonged ventilation 7.07 10.81 12.21 23.07
Reoperation for bleeding 4.12 4.65 5.49 5.87
Renal failure 3.70 5.23 6.48 12.51
Deep sternal infection 0.50 0.34 0.70 0.84
Length of hospital stay
(mean 6 SD)
10.6 6 9.6 12.8 6 12.6 12.5 6 11.2 16.0 6 15.3
Postoperative length of hospital
stay (mean 6 SD)
8.5 6 8.4 9.9 6 10.3 10.0 6 10.1 12.7 6 14.0
Abbreviations as in Table 1.
Table 3. Operative Mortality for Specific Subgroups by
Procedure Type
Risk Factor
AVR
Only
MVR
Only
CABG/
AVR
CABG/
MVR
Gender (%)
Male 3.62 5.74 5.88 10.85
Female 4.81 6.54 9.23 16.36
Diabetes (%)
Yes 6.64 11.09 8.97 18.38
No 3.67 5.62 6.31 11.87
Dialysis (%)
Yes 17.07 22.45 24.59 36.89
No 4.00 6.04 6.83 13.33
Cerebrovascular accident (%)
Yes 7.55 8.52 8.60 15.70
No 3.90 5.99 6.83 13.31
Triple-vessel disease (%)
Yes 10.09 16.55 8.57 15.97
No 4.05 6.14 5.97 11.73
Hypertension (%)
Yes 4.77 8.21 7.51 14.83
No 3.51 5.06 6.11 11.85
Chronic lung disease (%)
Yes 5.88 8.89 8.99 14.81
No 3.80 5.77 6.51 13.21
Peripheral vascular disease (%)
Yes 7.03 13.12 9.80 20.55
No 3.90 5.83 6.48 12.44
Immunosuppressive treatment (%)
Yes 8.41 11.59 12.36 21.21
No 4.02 6.11 6.86 13.38
Operative status (%)
Elective 3.30 4.22 5.86 6.01
Urgent 6.27 9.35 9.21 15.79
Emergent 17.22 23.48 15.53 29.35
Salvage 35.57 43.22 43.26 45.48
Previous cardiac operation (%)
Yes 7.64 9.25 11.69 14.33
No 3.55 5.09 6.31 13.40
Abbreviations as in Table 1.
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Model performance assessment. INTERNAL ASSESSMENT.
The c-index was 0.766 for the isolated valve model and
0.739 for the CABG/valve replacement model. Figures 1
and 2 compare predicted versus observed results for sub-
groups across the risk spectrum. Both models demonstrate
very good agreement between observed and predicted val-
ues.
EXTERNAL ASSESSMENT. The “test set” population con-
sisted of 25,640 patients undergoing isolated AVR or MVR
procedures and 25,852 undergoing combined CABG/valve
surgery between January 1998 and December 1999. Each
patient record in the test set was entered into the appropri-
ate model. The c-index for the isolated valve model was
0.773 and that for the CABG/valve model was 0.730. A
measure of calibration was determined by using the
Hosmer-Lemeshow goodness-of-fit statistic, which was
10.6 (p 5 0.225) for the isolated valve models and 12.2 (p 5
0.141) for CABG/valve models.
The overall predicted mortality rates for the 1998 to 1999
test set were very similar to the observed mortality rates
(Fig. 3 and 4). For the isolated valve model, the overall
predicted mortality rate was 4.8%, compared with an ob-
served rate of 4.7%. For the CABG/valve model, the
predicted mortality rate was 8.6%, compared with an 8.2%
observed mortality rate.
DISCUSSION
The quality of care provided by cardiac surgery programs
has traditionally been measured by the OM associated with
CABG. The use of statistical models of CABG mortality
has become commonplace, allowing sophisticated risk strat-
ification of patients undergoing CABG (2–6).
The results of valve replacement surgery should also be
considered an important element in the evaluation of
cardiac surgery results. Unfortunately, there have been few
national or large regional studies of valve surgery compara-
ble to those of coronary surgery. Accordingly, the risk
factors associated with valve surgery are more obscure, and
acceptable outcomes are more difficult to define. Risk
models have only recently been used to evaluate patients
undergoing valve replacement surgery (7,8).
Clinical application. The use of a national database has
obvious value in this context. The STS Database has
detailed preoperative, intraoperative and postoperative in-
formation on patients undergoing valve replacement surgery
in a wide variety of centers throughout the country. The
centers include academic, private, military and Veterans
Table 4. Risk Factors for Isolated Valve Surgery Model*
Risk Factor Prevalence†
Wald
Chi-Square
Value
Odds Ratio
(95% CI)
Salvage status 0.7 203.31 *
Emergency status 5.5 151.02 *
Previous cardiac operation(s) 18.3 100.68 1.66 (1.51–1.84)
Renal failure or creatinine
.2.0 mg/100 ml
5.4 90.69 2.08 (1.78–2.41)
Age 63.8 63.93 1.03 (1.02–1.04)
BSA 1.9 58.96 0.38 (0.29–0.48)
Dialysis-dependent renal
failure
1.5 39.59 2.19 (1.71–2.80)
Preoperative IABP or
inotropes
4.3 38.73 1.63 (1.40–1.90)
Diabetes 13.6 35.65 1.41 (1.26–1.57)
NYHA class IV 18.2 35.27 1.36 (1.23–1.51)
Active infectious endocarditis 3.0 30.50 1.72 (1.42–2.09)
MI within 3 weeks 1.6 24.23 1.76 (1.40–2.19)
Mitral valve replacement 32.8 23.25 *
Urgent status 13.2 19.11 1.31 (1.16–1.48)
Pulmonary hypertension 21.4 18.03 1.24 (1.12–1.37)
Chronic lung disease 15.1 13.86 1.23 (1.10–1.38)
Cerebrovascular accident 7.0 13.16 1.30 (1.13–1.50)
Hypertension 44.4 10.51 1.16 (1.06–1.27)
Peripheral vascular disease 6.3 8.28 1.24 (1.07–1.44)
* This model contains a linear spline for age with cut points at ages 50 and 75 years.
It also contains two interactions terms: age by MVR and age by emergency/salvage
status. As such, the odds ratio associated with age refers to a 50- to 74-year-old
undergoing AVR whose status was either elective or urgent. The odds ratios for
MVR, emergency status and salvage status vary according to age. † Percentages for
categoric variables; mean values for continuous variables.
BSA 5 body surface area; CI 5 confidence interval; IABP 5 intraoperative
balloon pump; MI 5 myocardial infarction; NYHA 5 New York Heart Association.
Table 5. Risk Factors for Coronary Artery Bypass Graft
Surgery/Valve Surgery Model*
Risk Factor Prevalence†
Wald
Chi-Square
Value
Odds Ratio
(95% CI)
Previous cardiac operation(s) 13.3 133.60 *
Renal failure or creatinine
.2.0 mg/100 ml
7.2 121.33 1.90 (1.70–2.13)
Salvage status 1.1 112.95 7.50 (5.15–10.85)
Emergency status 8.6 102.78 1.82 (1.62–2.04)
Mitral valve replacement 25.1 100.45 1.72 (1.54–1.91)
Age 71.1 98.85 1.04 (1.03–1.05)
Diabetes 24.9 54.71 1.35 (1.25–1.46)
Female gender 36.6 46.79 1.38 (1.26–1.51)
Dialysis-dependent renal
failure
1.3 43.58 2.15 (1.71–2.69)
Three-vessel CAD 39.5 40.85 1.27 (1.18–1.36)
Preoperative IABP or
inotropes
7.8 40.36 1.47 (1.30–1.65)
NYHA class IV 24.2 26.78 1.23 (1.14–1.34)
BSA 1.9 25.01 0.51 (0.39–0.66)
Ejection fraction 47.9 24.42 1.09 (1.05–1.12)
Pulmonary hypertension 17.4 18.32 1.28 (1.14–1.44)
MI within 24 h 1.3 17.55 1.63 (1.30–2.04)
MI within 1 week 7.0 17.01 1.31 (1.15–1.49)
Urgent status 19.6 16.34 1.20 (1.10–1.32)
Immunosuppressive treatment 2.0 13.45 1.48 (1.20–1.82)
Chronic lung disease 19.0 12.75 1.17 (1.07–1.28)
Peripheral vascular disease 14.4 6.96 1.17 (1.04–1.31)
* This model contains a linear spline for age with cut points at ages 50 and 75 years.
It also contains five interactions terms: age by previous cardiac operation(s), MVR by
previous cardiac operation(s), MVR by pulmonary hypertension, MVR by salvage
status and MVR by peripheral vascular disease (PVD). As such, the odds ratio for age
refers to a 50- to 74-year-old patient with no previous cardiac operations. The odds
ratios for pulmonary hypertension, salvage status and PVD refer to a patient receiving
AVR. The odds ratio for MVR refers to a patient who does not have pulmonary
hypertension, salvage status, PVD or previous cardiac operation(s). The odds ratio for
previous cardiac operation(s) varies according to age. † Percentages for categoric
variables; mean values for continuous variables.
CAD 5 coronary artery disease; other abbreviations as in Table 4.
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Affairs practices, which, in aggregate, should represent a
reasonable estimate of the “average” national experience.
The use of this population to develop statistical risk
models should serve as a unique benchmark for quality
assurance. With the risk models presented in this report, it
becomes possible for centers to obtain an objective and
reproducible estimate of OM based on national results. It is
instructive to illustrate this concept with an example: a given
institution seeking to assess its valve surgery OM may enter
its patient population into the STS models to generate a
predicted OM for each patient. The average predicted
mortality (P%) for the population is then calculated. The
following statement is warranted: “Based on the accumu-
lated experience of the STS Database, of every 100 patients
with comparable risk factors, P would be expected to die
after valve replacement surgery.” The actual OM for the
population should be compared with the predicted OM. If
there is no significant difference, it is reasonable to conclude
Figure 1. Observed versus predicted observed mortality for isolated aortic or mitral valve replacement. Data points correspond to decile subgroups of equal
size for the 1994 to 1997 data.
Figure 2. Observed versus predicted observed mortality for coronary artery bypass graft surgery combined with aortic or mitral valve replacement. Data
points correspond to decile subgroups of equal size for the 1994 to 1997 data.
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that the results of this institution conform with an accepted
national average. If there is a significant difference, it should
prompt the institution to investigate the issue more thor-
oughly. The STS holds the position that differences be-
tween predicted and actual OM rates do not invariably
signal substandard care, but such differences should be a
cause for more detailed examination (9).
Comparison with previous studies. The initial attempt to
model valve OM using the STS Database was begun five
years ago (7). This effort focused on the population from
1986 to 1995, which, in retrospect, constitutes a more
heterogeneous group of patients undergoing a broader array
of valve procedures. Furthermore, data gathered in the
1980s were not subject to the more rigorous screening
criteria imposed in the 1990s, so that a significant portion of
the 1986 to 1995 population may contain information that
does meet current quality standards. In addition, the STS
“core data set” variables had not been developed, so the
model risk factors include several variables that are not now
considered necessary for collection. These early models
served a useful purpose and provided a necessary step in the
evolution of our outcomes analyses; however, the present
Figure 3. Observed versus predicted observed mortality for isolated aortic or mitral valve replacement. Data points correspond to decile subgroups of equal
size for the 1998 to 1999 data.
Figure 4. Observed versus predicted observed mortality for coronary artery bypass graft surgery combined with aortic or mitral valve replacement. Data
points correspond to decile subgroups of equal size for the 1998 to 1999 data.
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models represent a clear improvement by obviating most of
the aforementioned shortcomings.
The pioneering work of the Veterans Affairs Cardiac
Surgery Consultants Committee has been particularly im-
portant in this field (5,8). The scientific development and
the practical application of risk models by this organization
have been exemplary, but their population, by design, is
restricted to Veterans Affairs centers. The select population
of Veterans Affairs hospitals may well preclude application
of their models on a broader scale.
Study limitations. Statistical risk models are valuable as
quality assurance tools and as aids to medical decision
making; however, one should not place an undue premium
on their value. Models should not dictate therapy, nor
should they arbitrarily brand a practice as “acceptable” or
“substandard.” They are designed to serve as aids, not to
serve as the answer. Results of risk models should be
generally considered as one would regard the results of a
laboratory test—one piece of the puzzle that should be
evaluated in concert with clinical judgment and other more
traditional forms of assessment (9–11).
The broad scope of the STS Database suggests that this
aggregate experience defines an acceptable standard of care.
Although this is a logical conclusion, it may not be true. It
is possible that regional geographic differences and select
referral patterns are so disparate that it is unreasonable to
hold all practices to a single standard. This issue is presently
under investigation by the STS Database Committee. For
now, it may be most appropriate to consider these data as a
“national average” rather than a “national standard” (9).
Future investigations. Operative mortality is certainly the
most important and the most easily measured of surgical
outcomes, but other outcomes also have a major impact on
patient care. We are presently developing models to predict
various forms of operative morbidity, with special emphasis
on postoperative neurologic dysfunction and the need for
prolonged ventilatory support. Models to predict length of
hospital stay and cost are also being investigated.
The STS has assisted with several regional and state
initiatives to gather and analyze data on a regional level.
These studies will be compared with national data to
determine whether significant differences exist. At this
point, one state has developed a risk model of CABG
mortality based solely on its state population. After exten-
sive testing of this “state model,” it was found to be
essentially identical to the national model. Future efforts
along these lines should determine whether the national
experience with cardiac surgery should be considered as a
standard of care or whether regionalization is necessary to
establish fair standards.
Conclusions. These STS risk models fill a void in our
ability to assess surgical outcomes associated with valve
replacement surgery. They allow one to determine the net
impact of all important preoperative risk factors to predict
the probability of postoperative mortality in patients under-
going valve surgery. This information, in turn, can be used
as a benchmark to compare risk-stratified patient groups
with a large multi-institutional experience that approxi-
mates a national standard of care.
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